Payment overview · 2025
General Payments
$413.84
19 reported records · 8 companies
Healthcare provider profile · identity verified
Laurence A Berarducci, M. D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · PUEBLO, CO · NPI 1669478541
Verified facts
What the public records show
CMS Open Payments records show Laurence A Berarducci, M. D. received $413.84 in general payments during 2025 across 19 reported records.
Boston Scientific Corporation accounted for 33.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Camzyos.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAMZYOS as an associated drug or biological on 41009 records involving 16400 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Camzyos by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 472 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $137.90 | 33.3% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $78.76 | 19.0% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $60.40 | 14.6% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.30 | 12.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.63 | 6.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.99 | 5.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.72 | 5.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.14 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $413.84 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $124.23 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $78.76 | 3 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $60.40 | 3 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $50.30 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.63 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| General - Tachy Normalized: general tachy |
Device | Boston Scientific Corporation | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAMZYOS camzyos |
2025 | Camzyos | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | CAMZYOS open payments reported associated product |
CMS Open Payments — General Payments 41009 supporting records · 16400 recipient NPIs · example record 1184377697 |
Camzyos · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
472 | 114 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
150 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
157 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 777 | 232 |
| Eliquis | Apixaban | 472 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 459 | 125 |
| Spironolactone | Spironolactone | 369 | 112 |
| Clopidogrel | Clopidogrel Bisulfate | 337 | 101 |
| Losartan Potassium | Losartan Potassium | 336 | 95 |
| Carvedilol | Carvedilol | 268 | 72 |
| Furosemide | Furosemide | 261 | 83 |
| Lisinopril | Lisinopril | 213 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 211 | 66 |
| Amiodarone Hcl | Amiodarone Hcl | 180 | 66 |
| Potassium Chloride | Potassium Chloride | 171 | 54 |
| Ezetimibe | Ezetimibe | 159 | 48 |
| Entresto | Sacubitril/Valsartan | 157 | 39 |
| Jardiance | Empagliflozin | 150 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 135 | 39 |
| Xarelto | Rivaroxaban | 125 | 31 |
| Farxiga | Dapagliflozin Propanediol | 105 | 30 |
| Repatha Sureclick | Evolocumab | 104 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 103 | 28 |
| Bumetanide | Bumetanide | 96 | 40 |
| Flecainide Acetate | Flecainide Acetate | 84 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 25 |
| Atenolol | Atenolol | 61 | 17 |
| Warfarin Sodium | Warfarin Sodium | 54 | 13 |
| Sotalol | Sotalol Hcl | 52 | 11 |
| Torsemide | Torsemide | 50 | 15 |
| Metolazone | Metolazone | 49 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 12 |
| Simvastatin | Simvastatin | 47 | suppressed |
| Nitroglycerin | Nitroglycerin | 45 | 24 |
| Camzyos | Mavacamten | 43 | suppressed |
| Vyndamax | Tafamidis | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 11 |
| Alprazolam | Alprazolam | 31 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 30 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 29 | suppressed |
| Verquvo | Vericiguat | 29 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Omeprazole | Omeprazole | 25 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 24 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Eplerenone | Eplerenone | 18 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Gabapentin | Gabapentin | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $413.84 · 19 records | Boston Scientific Corporation | AMVUTTRA, CAMZYOS, General - Tachy, General - Therapies, Kerendia, LEQVIO, REPATHA, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Camzyos play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error